Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress

Endocrinology

Volumn 148, Issue 2, 2007, Pages 548-558

  Vincent, Andrea M ^a   Perrone, Lorena ^a   Sullivan, Kelli A ^a   Backus, Carey ^a   Sastry, Ann Marie ^b   Lastoskie, Christian ^b   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CASPASE 3; CELL NUCLEUS DNA; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOCTIC ACID;

ANIMAL CELL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; DNA DEGRADATION; ENZYME ACTIVITY; HYPERGLYCEMIA; KIDNEY DISEASE; NERVE CELL LESION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINOPATHY; SENSORY NERVE CELL; SPINAL GANGLION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GANGLIA, SPINAL; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; INTRACELLULAR MEMBRANES; LIGANDS; NADPH OXIDASE; NEURONS, AFFERENT; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS; SIGNAL TRANSDUCTION;

EID: 33846460101     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0073     Document Type: Article

References (80)

1. Lee AT, Cerami A 1989 Nonenzymatic glycosylation of DNA by reducing sugars. Prog Clin Biol Res 304:291-299
2. Brownlee M 2000 Negative consequences of glycation. Metabolism 49:9-13
3. Ulrich P, Cerami A 2001 Protein glycation, diabetes, and aging. Recent Prog Horm Res 56:1-21
4. Thornalley PJ 2002 Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 50:37-57
5. King RH 2001 The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol Pathol 54:400-408
6. Layton BE, Sastry AM 2004 A mechanical model for collagen fibril load sharing in peripheral nerve of diabetic and non-diabetic rats. J Biomech Eng 126:803-814
7. Layton BE, Sastry AM, Wang H, Sullivan KA, Feldman EL, Komorowski TE, Philbert MA 2004 Differences between collagen morphologies, properties and distribution in diabetic and normal BioBreeding and Sprague-Dawley rat sciatic nerves. J Biomech 37:879-888
8. Wang H, Layton BE, Sastry AM 2003 Nerve collagens from diabetic and nondiabetic Sprague-Dawley and biobreeding rats: an atomic force microscopy study. Diabetes Metab Res Rev 19:288-298
9. Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, Brownlee M, Hanssen KF 2003 Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 52:163-167
10. Li B, Setoguchi M, Wang X, Andreoli AM, Leri A, Malhotra A, Kajstura J, Anversa P 1999 Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ Res 84:1007-1019
11. Schalkwijk CG, Ligtvoet N, Twaalfhoven H, Jager A, Blaauwgeers HG, Schlingemann RO, Tarnow L, Parving HH, Stehouwer CD, van Hinsbergh VW 1999 Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 48:2446-2453
12. Singh R, Barden A, Mori T, Beilin L 2001 Advanced glycation end-products: a review. Diabetologia 44:129-146
13. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan Y-CE, Elliston K, Stern D, Shaw A 1992 Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-15004
14. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M, Stern D 1996 RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 45(Suppl 3):S77-S80
15. Xu D, Kyriakis JM 2003 Phosphatidyl inositol-3′OH kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by advanced glycation end products. J Biol Chem 278:39349-39355
16. Zill H, Bek S, Hofmann T, Huber J, Frank O, Lindenmeier M, Weigle B, Erbersdobler HF, Scheidler S, Busch AE, Faist V 2003 RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. Biochem Biophys Res Commun 300:311-315
17. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T 2003 The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 550:107-113
18. Zill H, Gunther R, Erbersdobler HF, Folsch UR, Faist V 2001 RAGE expression and AGE-induced MAP kinase activation in Caco-2 cells. Biochem Biophys Res Commun 288:1108-1111
19. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY 2001 Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 81:102-113
20. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL 2001 Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685-E694
21. Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY 2004 Advanced glycation end products activate Smad signaling via TGF-β-dependent and -independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 18:176-178
22. Shaw SS, Schmidt AM, Banes AK, Wang X, Stern DM, Marrero MB 2003 S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes 52:2381-2388
23. Yamamoto Y, Yamagishi S, Yonekura H, Doi T, Tsuji H, Kato I, Takasawa S, Okamoto H, Abedin J, Tanaka N, Sakurai S, Migita H, Unoki H, Wang H, Zenda T, Wu PS, Segawa Y, Higashide T, Kawasaki K, Yamamoto H 2000 Roles of the AGE-RAGE system in vascular injury in diabetes. Ann NY Acad Sci 902:163-170
24. Stern DM, Yan SD, Yan SF, Schmidt AM 2002 Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 1:1-15
25. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D 1994 Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. J Biol Chem 269:9889-9897
26. Dukic-Stefanovic S, Gasic-Milenkovic J, Deuther-Conrad W, Munch G 2003 Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs). J Neurochem 87:44-55
27. Kuniyasu H, Chihara Y, Kondo H 2003 Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 104:722-727
28. Bartling B, Demling N, Silber RE, Simm A 2006 Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products. Am J Respir Cell Mol Biol 34:83-91
29. Shanmugam N, Kim YS, Lanting L, Natarajan R 2003 Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J Biol Chem 278:34834-34844
30. Li J, Schmidt AM 1997 Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 272:16498-16506
31. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP 2001 Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 50:2792-2808
32. Vlassara H 2001 The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 17:436-443
33. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM 1999 RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901
34. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka Y 2003 Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111:959-972
35. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM 2003 RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162:1123-1137
36. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD 2001 Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171:29-45
37. Sasaki N, Takeuchi M, Chowei H, Kikuchi S, Hayashi Y, Nakano N, Ikeda H, Yamagishi S, Kitamoto T, Saito T, Makita Z 2002 Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett 326:117-120
38. Ma L, Carter RJ, Morton AJ, Nicholson LF 2003 RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats. Brain Res 966:167-174
39. Haslbeck KM, Bierhaus A, Erwin S, Kirchner A, Nawroth P, Schlotzer U, Neundorfer B, Heuss D 2004 Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factor-κB activation in vasculitic neuropathy. Muscle Nerve 29:853-860
40. Rong LL, Yan SF, Wendt T, Hans D, Pachydaki S, Bucciarelli LG, Adebayo A, Qu W, Lu Y, Kostov K, Lalla E, Yan SD, Gooch C, Szabolcs M, Trojaborg W, Hays AP, Schmidt AM 2004 RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J 18:1818-1825
41. Russell JW, Sullivan KA, Windebank AJ, Herrmann DN, Feldman EL 1999 Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis 6:347-363
42. Feldman EL 2003 Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest 111:431-433
43. Russell JW, Golovoy D, Vincent AM, Mahendru P, Olzmann JA, Mentzer A, Feldman EL 2002 High glucose induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 16:1738-1748
44. Singleton JR, Smith AG, Russell JW, Feldman EL 2003 Microvascular complications of impaired glucose tolerance. Diabetes 52:2867-2873
45. Layton BE, Sastry AM, Lastoskie CM, Philbert MA, Miller TJ, Sullivan KA, Feldman EL, Wang C-W 2004 In situ imaging of mitochondrial outer-membrane pores using atomic force microscopy. Biotechniques 37:564-573
46. Shaw S, Akyol M, Bell J, Briggs JD, Dominiczak MH 1998 Effects of continuous ambulatory peritoneal dialysis and kidney transplantation on advanced glycation endproducts in the skin and peritoneum. Cell Mol Biol (Noisy-le-grand) 44:1061-1068
47. Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam BG, Murray-McIntosh RP, Cooper ME 1997 Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40:619-628
48. Vincent AM, McLean LL, Backus C, Feldman EL 2005 Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J 19:638-640
49. Vincent AM, Stevens MJ, Backus C, McLean LL, Feldman EL 2005 Cell culture modeling to test therapies against hyperglycemia-mediated oxidative stress and injury. Antiox Redox Signal 7:1494-1506
50. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD 2000 Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11:1656-1666
51. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM 1997 Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272:17810-17814
52. Vincent AM, Olzmann JA, Brownlee M, Sivitz WI, Russell JW 2004 Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death. Diabetes 53:726-734
53. Bhandari U, Kanojia R, Pillai KK 2002 Effect of ethanolic extract of Embelia ribes on dyslipidemia in diabetic rats. Int J Exp Diabetes Res 3:159-162
54. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A 2003 Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52:2795-2804
55. Li JM, Shah AM 2003 ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol 14:S221-S226
56. Leinninger GM, Backus C, Uhler MD, Lentz SI, Feldman EL 2004 Phosphatidylinositol 3-kinase and Akt effectors mediate insulin-like growth factor-I neuroprotection in dorsal root ganglia neurons. FASEB J 18:1544-1546
57. Vincent AM, Russell JW, Low P, Feldman EL 2004 Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 25:612-628
58. Young MR, Kolesiak K, Meisinger J 2002 Protein phosphatase-2A regulates endothelial cell motility and both the phosphorylation and the stability of focal adhesion complexes. Int J Cancer 100:276-282
59. Koliatsos VE, Cayouette MH, Berkemeier LR, Clatterbuck RE, Price DL, Rosenthal A 1994 Neurotrophin 4/5 is a trophic factor for mammalian facial motor neurons. Proc Natl Acad Sci USA 91:3304-3308
60. Fan C, Katsuyama M, Nishinaka T, Yabe-Nishimura C 2005 Transactivation of the EGF receptor and a PI3 kinase-ATF-1 pathway is involved in the upregulation of NOX1, a catalytic subunit of NADPH oxidase. FEBS Lett 579:1301-1305
61. Poolman TM, Ng LL, Farmer PB, Manson MM 2005 Inhibition of the respiratory burst by resveratrol in human monocytes: correlation with inhibition of PI3K signaling. Free Radic Biol Med 39:118-132
62. Stevens MJ, Obrosova I, Pop-Busui R, Greene DA, Feldman EL 2002 Pathogenesis of diabetic neuropathy. In: Porte Jr D, Sherwin RS, Baron A, eds. Ellenberg and Rifkin's diabetes mellitus. 6th ed. New York: McGraw Hill; 747-770
63. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern DM, Naka Y, Ramasamy R, Yan SD, Yan SF, D'Agati V, Schmidt AM 2003 Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 419:80-88
64. Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, Rasch R 2004 Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53:166-172
65. Li J, Qu X, Schmidt AM 1998 Sp1-binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells. J Biol Chem 273:30870-30878
66. Hou FF, Ren H, Owen Jr WF, Guo ZJ, Chen PY, Schmidt AM, Miyata T, Zhang X 2004 Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 15:1889-1896
67. Vincent AM, Mobley BC, Hiller A, Feldman EL 2004 IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis 16:407-416
68. Leinninger GM, Vincent AM, Feldman EL 2004 The role of growth factors in diabetic peripheral neuropathy. J Periph Nerv Syst 9:26-53
69. Kim B, Leventhal PS, White MF, Feldman EL 1998 Differential regulation of insulin receptor substrate-2 and mitogen-activated protein kinase tyrosine phosphorylation by phosphatidylinositol 3-kinase inhibitors in SH-SY5Y human neuroblastoma cells. Endocrinology 139:4881-4889
70. Feldman EL, Sullivan KA, Kim B, Russell JW 1997 Insulin-like growth factors regulate neuronal differentiation and survival. Neurobiol Dis 4:201-214
71. Zhang H, Hoff H, Sell C 2003 Downregulation of IRS-1 protein in thapsigargin-treated human prostate epithelial cells. Exp Cell Res 289:352-358
72. Choi MH, Lee IK, Kim GW, Kim BU, Han YH, Yu DY, Park HS, Kim KY, Lee JS, Choi C, Bae YS, Lee BI, Rhee SG, Kang SW 2005 Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature 435:347-353
73. Vincent AM, Feldman EL 2002 Control of cell survival by IGF signaling pathways. Growth Horm IGF Res 12:193-197
74. Brownlee M 2001 Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820
75. Rhee SG, Bae YS, Lee SR, Kwon J 2000 Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. Sci STKE 2000:E1
76. Cotter MA, Cameron NE 2003 Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci 73:1813-1824
77. Matsunaga-Irie S, Maruyama T, Yamamoto Y, Motohashi Y, Hirose H, Shimada A, Murata M, Saruta T 2004 Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G1704T gene polymorphisms in type 2 diabetic patients. Diabetes Care 27:303-307
78. Takeya R, Sumimoto H 2003 Molecular mechanism for activation of superoxide-producing NADPH oxidases. Mol Cells 16:271-277
79. Cai H, Griendling KK, Harrison DG 2003 The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24:471-478
80. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y, Ohtoshi K, Hayaishi-Okano R, Kosugi K, Hori M, Yamasaki Y 2005 Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28:2716-2721